Full Press Release Details
Biote Reports Fourth Quarter and Full Year 2022 Financial Results
Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022
Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of
Significantly Increased Trading Liquidity with Recent Successful
IRVING, TX March 28, 2023 Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care
through the delivery of personalized hormone therapy, today announced financial results for the fourth quarter and full year ended December 31, 2022.
Fourth Quarter Highlights, year over year:
Full Year 2022 Highlights, year over year:
Biote achieved record financial results in the fourth quarter and for the full 2022 year, driven by strong growth in revenue and
Adjusted EBITDA, which were at the high end of our guidance, said Biote Chief Executive Officer Terry Weber. Our financial performance reflected successful execution of our growth strategy, as we further built our sales team and
practitioner network in both existing and new geographic markets. Consumers increasingly seek treatment for many age-related symptoms often caused by hormonal imbalances, and the effectiveness of the Biote
method continues to spur patient demand for the customized therapies offered by Biote-certified providers. As we strive to make the Biote brand synonymous with hormone replacement therapy, we remain dedicated to broadening public awareness by
advancing the science and research supporting hormone optimization.
Ms. Weber continued, In early January, we successfully completed a secondary offering of Biote
Class A common stock, representing an important milestone in our journey as a public company. This transaction not only significantly increased the liquidity of our publicly traded shares, but also broadened institutional ownership of our
shares. As a management team, we remain focused on building long-term shareholder value through profitable growth.
2022 Fourth Quarter Financial
Revenue for the fourth quarter of 2022 was $44.5 million, an increase of 18.5% from $37.5 million for the fourth quarter of 2021. The
increase was driven by continued growth in both procedures and dietary supplements revenue, despite lingering weather-related impacts in Florida and Puerto Rico.
Gross profit margin for the fourth quarter of 2022 was 65.3% compared to 64.0% for the fourth quarter of 2021. The increase in gross profit margin was
primarily due to effective cost management.
Operating income for the fourth quarter of 2022 was $7.3 million, an increase of 23.3% from
$5.9 million in the fourth quarter of 2021. The increase in operating income reflected increased profitability on higher sales, partially offset by higher SG&A expense.
Net income for the fourth quarter of 2022 was $12.8 million, or $0.18 per diluted share, compared to net income of $5.5 million for the fourth
quarter of 2021. Net income increased due to the improvement in operating income and a favorable impact from transaction-related items, partially offset by increased interest expense. The net change in the fair value adjustments to warrant and
earnout liabilities was $7.5 million in the fourth quarter, as compared to no such impact in the fourth quarter of 2021.
Adjusted EBITDA for the
fourth quarter of 2022 was $13.1 million compared to $9.4 million for the fourth quarter of 2021. The 40% increase in Adjusted EBITDA was driven by the growth in revenue as well as the positive leverage in our business model that enables
profit to grow faster than revenue.3
2022 Full Year Financial Review
Revenue for 2022 was $165.0 million, an increase of 18.3% from $139.4 million in 2021. The increase was driven by continued growth in both procedures
and dietary supplements revenue.
Gross profit margin for 2022 was 66.9% compared to 65.0% for 2021. The increase in gross profit margin was primarily due
to a more favorable product mix.
Operating loss for 2022 was $(60.7) million, compared to operating income of $34.6 million for 2021. Operating loss
in 2022 reflected the impact of $21.6 million in transaction-related costs and $82.2 million in stock compensation expense. Excluding these costs, operating income would have been $43.1 million in 2022.
Net income for 2022 was $1.3 million, or a loss of $0.12 per diluted share, compared to net income of $32.6 million in the fourth quarter of 2021.
Adjusted EBITDA for 2022 was $50.1 million compared to $40.2 million for 2021. The 24.6% increase
in Adjusted EBITDA was primarily driven by the growth in revenue and the positive operating leverage in our business model.4
2023 Financial Outlook
Biote s annuity-like
business model provides good visibility into our projected financial performance. In 2023 we anticipate continued growth in both revenue and Adjusted EBITDA, as we further build our market presence and practitioner network. We are investing to
strengthen our infrastructure and capabilities while continuing to expand our sales team, said Ms. Weber.
Our 2023 financial forecast
assumes stronger revenue growth and Adjusted EBITDA performance in the second half of the year as we begin to benefit from the contributions of sales personnel added at the end of last year, concluded Ms. Weber.
| ($in millions) | 2023 Guidance Range | |||
| Revenue | $ | 190-$200 | ||
| Adjusted EBITDA | $ | 56-$60 |
Weber, Chief Executive Officer, and the Company s management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, March 29, 2023. To access the conference call by
telephone, please dial (866) 524-3160 (U.S toll-free) or (412) 317-6760 (International). To access a live webcast of the call, interested parties may use the following
link: Biote Q4 and Full Year 2022 Earnings Webcast. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, at ir.biote.com, shortly after the event concludes.
Discussion of Non-GAAP Financial Measures
To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a
non-GAAP financial measure that it calculates as net income before interest, taxes and depreciation and amortization, further adjusted to exclude stock-based compensation, transaction-related expenses, fair
value adjustments to certain equity instruments classified as liabilities and other non-operating costs. Below we have provided a reconciliation of net income (the most directly comparable GAAP financial
measure) to Adjusted EBITDA.
We present Adjusted EBITDA because it is a key measure used by our management to evaluate our operating performance,
generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same
manner as our management.
Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a
substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:
In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgment by Biote s management
about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each non-GAAP financial measure to the most directly
comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including net income and our other GAAP results.
Biote is transforming healthy aging through
innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $7 billion global
market, providing affordable symptom relief for patients and driving clinic success for practitioners.
Forward-Looking Statements
Except for historical information contained herein, this press release contains certain forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in
nature, including the words may, can, should, will, estimate, plan, project, forecast, intend, expect, hope,
anticipate, believe, seek, target, continue, could, might, ongoing, potential, predict, would and other similar
expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject
to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to
attain significant market acceptance among clinics, practitioners and their patients; our customers reliance on certain third parties to support the manufacturing of bio-identical hormones for
prescribers; our and our customers sensitive to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we
anticipate or at all; our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our
intellectual property; the unpredictability of the effects of the COVID-19 pandemic; the heavy regulatory oversight in our industry; changes in applicable
laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including recent bank failures; and future
exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Risk Factors section of Biote s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2022 and other documents filed by Biote from time to time with the Securities and Exchange Commission, including our Annual
Report on Form 10-K for the year ended December 31, 2022. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does
not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.
Consolidated Balance
| December 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 79,231 | $ | 26,766 | ||||
| Accounts receivable, net | 6,948 | 5,231 | ||||||
| Inventory, net | 11,183 | 9,615 | ||||||
| Other current assets | 3,816 | 5,473 | ||||||
| Total current assets | 101,178 | 47,085 | ||||||
| Property and equipment, net | 1,504 | 2,335 | ||||||
| Capitalized software, net | 5,073 | 4,554 | ||||||
| Operating lease right-of-use assets | 2,052 | 356 | ||||||
| Deferred tax asset | 1,838 | |||||||
| Total assets | $ | 111,645 | $ | 54,330 | ||||
| Liabilities and Stockholders Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,112 | $ | 4,349 | ||||
| Accrued expenses | 6,274 | 6,011 | ||||||
| Term loan, current | 6,250 | 5,000 | ||||||
| Deferred revenue, current | 1,965 | 1,705 | ||||||
| Operating lease liabilities, current | 165 | 248 | ||||||
| Total current liabilities | 18,766 | 17,313 | ||||||
| Term loan, net of current portion | 112,086 | 31,963 | ||||||
| Deferred revenue, net of current portion | 926 | 802 | ||||||
| Operating lease liabilities, net of current portion | 1,927 | 127 | ||||||
| Warrant liability | 4,104 | |||||||
| Earnout liability | 32,110 | |||||||
| Total liabilities | 169,919 | 50,205 | ||||||
| Commitments and contingencies (See Note 18) | ||||||||
| Stockholders Equity (Deficit) | ||||||||
| Class A, AA, AAA, and AAAA units, no par value, unlimited units authorized; no and 1,013,197 units issued, no and 982,800 units outstanding as of December 31, 2022 and December 31, 2021, respectively | ||||||||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding | ||||||||
| Class A common stock, $0.0001 par value, 600,000,000 shares authorized; 11,242,887 and no shares issued, 9,655,387 and no shares outstanding as of December 31, 2022 and December 31, 2021, respectively | 1 | |||||||
| Class B common stock, $0.0001 par value, 8,000,000 shares authorized; no shares issued or outstanding as of December 31, 2022 and December 31, 2021 | ||||||||
| Class V voting stock, $0.0001 par value, 100,000,000 shares authorized; 58,565,824 and no shares issued, 48,565,824 and no shares outstanding as of December 31, 2022 and December 31, 2021, respectively | 5 | |||||||
| Additional paid-in capital | ||||||||
| Retained earnings (Accumulated deficit) | (44,460 | ) | 4,165 | |||||
| Accumulated other comprehensive loss | (5 | ) | (40 | ) | ||||
| biote Corp. s stockholders equity (deficit) | (44,459 | ) | 4,125 | |||||
| Noncontrolling interest | (13,815 | ) | ||||||
| Total stockholders equity (deficit) | (58,274 | ) | 4,125 | |||||
| Total liabilities and stockholders equity (deficit) | $ | 111,645 | $ | 54,330 |
Consolidated Statements of Operations
(In Thousands, except per share values)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 44,012 | $ | 36,979 | $ | 163,133 | $ | 137,598 | ||||||||
| Service revenue | 473 | 557 | 1,824 | 1,798 | ||||||||||||
| Total revenue | 44,485 | 37,536 | 164,957 | 139,396 | ||||||||||||
| Cost of revenue (excluding depreciation and amortization included in selling, general and administrative, below) | ||||||||||||||||
| Cost of products | 14,599 | 12,802 | 51,990 | 46,298 | ||||||||||||
| Cost of services | 825 | 724 | 2,585 | 2,519 | ||||||||||||
| Cost of revenue | 15,424 | 13,526 | 54,575 | 48,817 | ||||||||||||
| Commissions | 186 | 449 | 974 | 2,056 | ||||||||||||
| Marketing | 1,276 | 1,683 | 4,628 | 4,908 | ||||||||||||
| Selling, general and administrative | 20,296 | 15,953 | 165,502 | 49,054 | ||||||||||||
| Income (loss) from operations | 7,303 | 5,925 | (60,722 | ) | 34,561 | |||||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest expense | (2,182 | ) | (372 | ) | (5,091 | ) | (1,673 | ) | ||||||||
| Gain from change in fair value of warrant liability | 575 | 5,127 | ||||||||||||||
| Gain from change in fair value of earnout liability | 6,930 | 61,770 | ||||||||||||||
| Loss from extinguishment of debt | (445 | ) | ||||||||||||||
| Other income | 619 | 4 | 1,073 | 17 | ||||||||||||
| Total other income (expense), net | 5,942 | (368 | ) | 62,434 | (1,656 | ) | ||||||||||
| Income before provision for income taxes | 13,245 | 5,557 | 1,712 | 32,905 | ||||||||||||
| Income tax expense | 436 | 77 | 388 | 286 | ||||||||||||
| Net income | 12,809 | 5,480 | 1,324 | 32,619 | ||||||||||||
| Less: Net income attributable to noncontrolling interest | 11,187 | 2,293 | ||||||||||||||
| Net income (loss) attributable to biote Corp. stockholders | 1,622 | (969 | ) | |||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustments | (1 | ) | (3 | ) | (1 | ) | (17 | ) | ||||||||
| Other comprehensive income (loss) | (1 | ) | (3 | ) | (1 | ) | (17 | ) | ||||||||
| Comprehensive income | $ | 12,808 | $ | 5,477 | $ | 1,323 | $ | 32,602 | ||||||||
| Net income (loss) per common share | ||||||||||||||||
| Basic | $ | 0.19 | $ | (0.12 | ) | |||||||||||
| Diluted | $ | 0.18 | $ | (0.12 | ) | |||||||||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 8,703,533 | 8,059,371 | ||||||||||||||
| Diluted | 58,750,051 | 8,059,371 |
Consolidated Statements of Cash Flows
| Year Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Operating Activities | ||||||||
| Net income | $ | 1,324 | $ | 32,619 | ||||
| Adjustments to reconcile net income to net cash (used in) provided by operating activities: | ||||||||
| Depreciation and amortization | 2,199 | 1,400 | ||||||
| Bad debt expense (recoveries) | (155 | ) | 240 | |||||
| Amortization of debt issuance costs | 589 | 222 | ||||||
| Provision for obsolete inventory | 140 | 471 | ||||||
| Non-cash lease expense | 240 | 226 | ||||||
| Non-cash sponsor share transfers | 7,216 | |||||||
| Non-cash fees under SEPA | 119 | |||||||
| Share-based compensation expense | 82,180 | |||||||
| Gain from change in fair value of warrant liability | (5,127 | ) | ||||||
| Gain from change in fair value of earnout liability | (61,770 | ) | ||||||
| Loss from extinguishment of debt | 445 | |||||||
| Deferred income taxes | (743 | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (1,562 | ) | (752 | ) | ||||
| Inventory | (1,708 | ) | (5,762 | ) | ||||
| Other current assets | (2,284 | ) | 34 | |||||
| Accounts payable | 416 | 1,605 | ||||||
| Deferred revenue | 384 | (373 | ) | |||||
| Accrued expenses | (30,841 | ) | 4,029 | |||||
| Operating lease liabilities | (219 | ) | (239 | ) | ||||
| Net cash (used in) provided by operating activities | (9,157 | ) | 33,720 | |||||
| Investing Activities | ||||||||
| Purchases of property and equipment | (333 | ) | (1,448 | ) | ||||
| Purchases of capitalized software | (1,505 | ) | (2,359 | ) | ||||
| Net cash used in investing activities | (1,838 | ) | (3,807 | ) | ||||
| Financing Activities | ||||||||
| Proceeds from the Business Combination | 12,282 | |||||||
| Principal repayments on term loan | (4,375 | ) | (5,000 | ) | ||||
| Borrowings on term loan | 125,000 | |||||||
| Extinguishment of Bank of America term loan | (36,250 | ) | ||||||
| Debt issuance costs | (4,036 | ) | ||||||
| Settlement of phantom equity rights | (7,250 | ) | ||||||
| Settlement of RSUs | (424 | ) | ||||||
| Distributions | (12,886 | ) | (11,402 | ) | ||||
| Capitalized transaction costs | (8,341 | ) | (3,941 | ) | ||||
| Proceeds from issuance of shares under SEPA | 442 | |||||||
| SEPA transaction costs | (702 | ) | ||||||
| Net cash provided by (used in) financing activities | 63,460 | (20,343 | ) | |||||
| Effect of exchange rate changes on cash and cash equivalents | (12 | ) | ||||||
| Net increase in cash and cash equivalents | 52,465 | 9,558 | ||||||
| Cash and cash equivalents at beginning of period | 26,766 | 17,208 | ||||||
| Cash and cash equivalents at end of period | $ | 79,231 | $ | 26,766 | ||||
| Supplemental Disclosure of Cash Flow Information | ||||||||
| Cash paid for interest | $ | 4,426 | $ | 1,462 | ||||
| Cash paid for income taxes | 282 | 171 | ||||||
| Non-cash investing and financing activities | ||||||||
| Capital expenditures and capitalized software included in accounts payable | $ | 49 | $ | 282 | ||||
| Non-cash SEPA transaction costs | $ | 119 | $ |
Reconciliation of Adjusted EBITDA to Net (Loss) Income
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net income | $ | 12,809 | $ | 5,480 | $ | 1,324 | $ | 32,619 | ||||||||
| Interest expense | 2,182 | 372 | 5,091 | 1,673 | ||||||||||||
| Income tax expense | 436 | 77 | 388 | 286 | ||||||||||||
| Depreciation and amortization | 555 | 413 | 2,199 | 1,400 | ||||||||||||
| Loss from extinguishment of debt and other non-operating items | (619 | ) | (4 | ) | (628 | ) | (17 | ) | ||||||||
| Share-based compensation expense | 2,164 | 82,180 | ||||||||||||||
| Transaction-related expenses | 978 | 1,503 | 21,627 | 2,387 | ||||||||||||
| Litigation and other | 2,118 | 1,531 | 4,843 | 1,869 | ||||||||||||
| Gain from change in fair value of warrant liability | (575 | ) | (5,127 | ) | ||||||||||||
| Gain from change in fair value of earnout liability | (6,930 | ) | (61,770 | ) | ||||||||||||
| Adjusted EBITDA | $ | 13,118 | $ | 9,373 | $ | 50,127 | $ | 40,218 |